Exact Sciences Stock Forecast, Price & News

Exact Sciences (NASDAQ:EXAS) Frequently Asked Questions

Is Exact Sciences a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences or view top-rated stocks.

How has Exact Sciences' stock price been impacted by Coronavirus (COVID-19)?

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EXAS stock has increased by 38.8% and is now trading at $80.28.
View which stocks have been most impacted by COVID-19.

Are investors shorting Exact Sciences?

Exact Sciences saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 12,750,000 shares, an increase of 19.4% from the September 30th total of 10,680,000 shares. Based on an average daily volume of 1,390,000 shares, the short-interest ratio is currently 9.2 days.
View Exact Sciences' Short Interest.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Exact Sciences.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) released its quarterly earnings data on Monday, November, 1st. The medical research company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.08. The medical research company had revenue of $456.38 million for the quarter, compared to the consensus estimate of $429.04 million. Exact Sciences had a negative net margin of 46.14% and a negative trailing twelve-month return on equity of 11.53%. During the same period last year, the business earned ($0.36) EPS.
View Exact Sciences' earnings history.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.72 billion-$1.74 billion, compared to the consensus revenue estimate of $1.73 billion.

What price target have analysts set for EXAS?

13 brokerages have issued 1 year price targets for Exact Sciences' stock. Their forecasts range from $95.00 to $168.00. On average, they anticipate Exact Sciences' stock price to reach $140.38 in the next twelve months. This suggests a possible upside of 74.9% from the stock's current price.
View analysts' price targets for Exact Sciences or view top-rated stocks among Wall Street analysts.

What are Wall Street analysts saying about Exact Sciences stock?

Here are some recent quotes from research analysts about Exact Sciences stock:

• 1. According to Zacks Investment Research, "Exact Sciences has underperformed its industry in the past three months. The company exited the second quarter of 2021 with net loss wider than the Zacks Consensus Estimate. The widening of quarterly operating and net loss compared to the year-ago period is concerning. Revenues from the COVID-19 tests conducted during the quarter declined year over year. Further, Screening revenues registered a onetime downward adjustment of $12 million. The company also incurred significant operating loss on escalating costs and expenses. On a positive note, Exact Sciences reported better-than-expected revenues in the second quarter. Robust total revenue growth during the quarter, despite the pandemic-led headwinds, is impressive. The company’s legacy Screening business saw a significant improvement in revenues on Cologuard volume growth." (9/29/2021)
• 2. The Goldman Sachs Group, Inc. analysts commented, " (6/3/2021)

Who are Exact Sciences' key executives?

Exact Sciences' management team includes the following people:

• Kevin T. Conroy, Chairman, President & Chief Executive Officer (LinkedIn Profile)
• Ana Hooker, Senior Vice President-Operations
• Jeffrey Thomas Elliott, Executive VP, Chief Operating & Financial Officer (LinkedIn Profile)
• Graham Peter Lidgard, Chief Science Officer, SVP-Research & Development
• Sandra Statz, Senior VP-Clinical & Regulatory Affairs

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Exact Sciences' key competitors?

Some companies that are related to Exact Sciences include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Novavax (NVAX), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of EXAS's competitors.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital World Investors (3.46%), Sumitomo Mitsui Trust Holdings Inc. (2.72%), Baillie Gifford & Co. (2.59%), Nikko Asset Management Americas Inc. (2.44%), Spyglass Capital Management LLC (1.31%) and Geode Capital Management LLC (1.22%). Company insiders that own Exact Sciences stock include Canada Pension Plan Investment, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella and Torsten Hoof.
View institutional ownership trends for Exact Sciences.

Which major investors are selling Exact Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Lombard Odier Asset Management Switzerland SA, Artisan Partners Limited Partnership, Voya Investment Management LLC, Principal Financial Group Inc., Frontier Capital Management Co. LLC, GABELLI & Co INVESTMENT ADVISERS INC., and Jennison Associates LLC. Company insiders that have sold Exact Sciences company stock in the last year include Canada Pension Plan Investment, Graham Peter Lidgard, Jacob A Orville, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, and Sarah Condella.
View insider buying and selling activity for Exact Sciences or view top insider-selling stocks.

Which major investors are buying Exact Sciences stock?

EXAS stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Spyglass Capital Management LLC, Capital World Investors, Farallon Capital Management LLC, US Bancorp DE, Pura Vida Investments LLC, and Bellevue Group AG.
View insider buying and selling activity for Exact Sciences or or view top insider-buying stocks.

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $80.28.

How much money does Exact Sciences make?

Exact Sciences has a market capitalization of $13.83 billion and generates $1.49 billion in revenue each year. The medical research company earns $-848.53 million in net income (profit) each year or ($4.97) on an earnings per share basis.

How many employees does Exact Sciences have?

Exact Sciences employs 5,000 workers across the globe.

Does Exact Sciences have any subsidiaries?

The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

What is Exact Sciences' official website?

The official website for Exact Sciences is www.exactsciences.com.

Where are Exact Sciences' headquarters?

Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at (608) 284-5700, via email at [email protected], or via fax at 608-284-5701.